TelyRx Announces Departure of Chief Revenue Officer
Clearwater, Florida--(Newsfile Corp. - November 18, 2026) - TelyRx Holdings Inc. (TSX: TELY) (OTCQX: TELYF) ("TelyRx" or the "Company"), a technology-enabled healthcare and digital pharmacy platform, today announced that Peter Lloyd, Chief Revenue Officer, is leaving the Company to pursue other opportunities. The Chief Revenue Officer's responsibilities will be shared among the existing leadership team in the interim. "On behalf of the Board and
Healthcare and Hospitals, Health
2026-11-18 9:15 AM EST | TelyRx
Envoy Medical Expands Intellectual Property Portfolio to 99 Patents with New U.S. and Hong Kong Patent Grants
White Bear Lake, Minnesota--(Newsfile Corp. - November 17, 2026) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health and neuroprosthetics company pioneering fully implanted hearing solutions, today announced it has been granted two additional patents in the United States and Hong Kong, bringing its intellectual property portfolio to 99 patents. In addition, the Company has 24 pending foreign applications and eight pending U.S. applications, further
Biotechnology, Healthcare and Hospitals
2026-11-17 9:15 AM EST | Envoy Medical, Inc.
Cambridge Manor Awarded ENERGY STAR(R) Canada Senior Living Building of the Year
Calgary, Alberta--(Newsfile Corp. - November 17, 2026) - Optima Living is pleased to announce that Cambridge Manor has been awarded ENERGY STAR® Canada's Building of the Year in the Senior Living Community and Residential Care Facility category. Presented by Natural Resources Canada, the ENERGY STAR Canada Awards recognize businesses, organizations and buildings that have demonstrated excellence in advancing energy efficiency. Cambridge Manor operated at more than 90% energy
2026-11-17 9:00 AM EST | Optima Seniors Management Inc.
ADIA Med Nearly Doubles Nine-Month Revenue to Surpass $1 Million
Winter Park, Florida--(Newsfile Corp. - November 17, 2026) - ADIA Med, Inc. (OTCQB: ADIA) today announced that revenue for the nine months ended September 30, 2026 rose approximately 95% to $1,019,245, up from $521,958 in the same period last year, crossing the $1 million mark.
Healthcare and Hospitals, Health
2026-11-17 8:00 AM EST | Adia Med Inc.
NuGen Medical Devices Provides Update on Health Canada Licence Application
Toronto, Ontario--(Newsfile Corp. - November 13, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company"), a developer of needle-free drug delivery technology, provides an update regarding its Canadian medical device licence for the InsuJet™ needle-free insulin injection system. Further to the Company's news release dated February 5, 2026, Health Canada has issued a Notice of Refusal in respect of the Company's Class II medical device licence application n
Healthcare and Hospitals, Pharmaceuticals, Health
2026-11-13 5:15 PM EST | NuGen Medical Devices Inc.
Vesalius Longevity Labs Appoints Harvey Spevak as Chairman to Accelerate Global Growth and Brand Development
British Columbia and Scottsdale, Arizona--(Newsfile Corp. - November 13, 2026) - Vesalius Longevity Labs Inc. (CSE: VLAB)("Vesalius" or the "Company"), a leading global peptide and longevity company, today announced the appointment of Harvey Spevak, as Chairman of its Board of Directors, effective November 13, 2026. The appointment follows
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-11-13 7:00 AM EST | Vesalius Longevity Labs Inc.
ALZAI Health Corp. Enters into MOU with Quanterix Corporation to Advance Early Alzheimer's Disease Identification
Toronto, Ontario--(Newsfile Corp. - November 13, 2026) - ALZAI Health Corp. (TSXV: ALZI) (OTCQB: ALZIF) (FSE: H2F) ("ALZAI" or the "Company"), a healthcare technology company developing artificial intelligence-driven disease risk identification solutions, is pleased to announce that it has entered into a Memorandum of Understanding ("MOU") with Quanterix Corporation ("Quanterix"), a leader in ultra-sensitive biomarker detection and blood-based diagnostic testing, to explore collaboration oppo
Technology, Computer Software, Healthcare and Hospitals
2026-11-13 6:00 AM EST | Alzai Health Corp.
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2027 ended September 30, 2026 and Provides Conference Call Information
Northvale, New Jersey--(Newsfile Corp. - November 12, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the Second quarter of fiscal year 2027 ended September 30, 2026 ("Second Quarter"). Consolidated revenues for the three-month period ending September 30, 2026, were $40.1 million, an increase of $3.8 million or approximately 10.4% as compared to the same pe
Healthcare and Hospitals, Pharmaceuticals, Health
2026-11-12 4:38 PM EST | Elite Pharmaceuticals, Inc.
KALA BIO Announces Reverse Stock Split
Arlington, Massachusetts--(Newsfile Corp. - November 12, 2026) - KALA BIO, Inc. (NASDAQ: KALA) ("KALA BIO" or the "Company"), today announced that it intends to effect a reverse stock split of its common stock, par value $0.001 per share (the "common stock"), at a ratio of 1 post-split share for every 30 pre-split shares. The reverse stock split will become effective at 4:05 p.m. on Friday, November 13, 2026. The Company's common stock will continue to be traded on the Nasdaq Capital M
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-11-12 8:00 AM EST | KALA Bio Inc.
TelyRx Appoints Co-Founder Benjamin Atkins as Interim Chief Executive Officer and President
Clearwater, Florida--(Newsfile Corp. - November 12, 2026) - TelyRx Holdings Inc. (TSX: TELY) (OTCQX: TELYF) ("TelyRx" or the "Company"), a technology-enabled healthcare and digital pharmacy platform, today announced that its Board of Directors has appointed Benjamin Atkins, a co-founder of the Company and a member of its Board, as Interim Chief Executive Officer and President, effective today. Mr. Atkins succeeds Vanessa Slowey, who is stepping down to pursue other commitments.
Healthcare and Hospitals, Health
2026-11-12 7:57 AM EST | TelyRx
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - November 12, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Com
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-11-12 7:00 AM EST | Phio Pharmaceuticals Corp.
Vesalius Longevity Labs Commences Trading Today on the Canadian Securities Exchange Under the Symbol "VLAB"
British Columbia and Scottsdale, Arizona--(Newsfile Corp. - November 12, 2026) - Vesalius Longevity Labs Inc. (CSE: VLAB) ("Vesalius" or the "Company") is pleased to announce that it will commence trading on the Canadian Securities Exchange ("CSE") under the symbol "VLAB" today, November 12, 2026. "Today marks an important milestone for Vesalius Labs, and I want to
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-11-12 7:00 AM EST | Vesalius Longevity Labs Inc.
Medexus Announces Strong Fiscal Q2 2027 Results Driven By Record Product-Level Performance of GRAFAPEX (Treosulfan) for Injection
Fiscal Q2 2027 net revenue of $29.1 million, Adjusted EBITDA* of $5.1 million, operating income of $2.4 million, and net income of $0.8 million - all quarterly records since fiscal Q4 2025, demonstrating significant year-over-year growth Product-level net revenue* from GRAFAPEX™ (treosulfan) for Injection of $5.7 million also a quarterly record Management to host conference c
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-11-11 5:30 PM EST | Medexus Pharmaceuticals Inc.
FendX Announces Proposed Name Change
Vancouver, British Columbia--(Newsfile Corp. - November 10, 2026) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), announces the Company's intention to change its name to Marlin Health Inc., and change its symbol on the Canadian Securities Exchange to "MRLH". The Canadian Securities Exchange ("CSE") will publish a bulletin announcing the effective date of the name and symbol change, and the Company's new CUSIP and ISIN nu
Technology, Healthcare and Hospitals, Health
2026-11-10 5:00 PM EST | Marlin Health Inc.
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter of Fiscal Year 2027 Financial Results on November 13, 2026
Northvale, New Jersey--(Newsfile Corp. - November 10, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the second quarter financial results of the 2027 fiscal year will be released on Thursday, November 12, 2026. Elite's management will host a live conference call on Friday, November 13, at 11:30 AM EST to discuss the company's financial and operating results and p
Healthcare and Hospitals, Pharmaceuticals, Health
2026-11-10 2:54 PM EST | Elite Pharmaceuticals, Inc.
Envoy Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement
White Bear Lake, Minnesota--(Newsfile Corp. - November 10, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health and neuroprosthetics company pioneering fully implanted hearing solutions, today announced that it has received written notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(1), the minimum bid price requirement, as the closing bid price of the Comp
Biotechnology, Healthcare and Hospitals
2026-11-10 8:30 AM EST | Envoy Medical, Inc.
HEALWELL More than Doubles YoY Adjusted EBITDA in Q3-2026 and Improves YTD Operating Cashflow by $26 Million
HEALWELL achieved revenue from continuing operations of $32.6 million in Q3-2026, an increase of 7% compared to revenue of $30.4 million in Q3-2025. HEALWELL reported positive Adjusted EBITDA1 of $1.6 million in Q3-2026, an increase of 144% compared to Adjusted EBITDA of $0.7 million in Q3-2025. The improvement in Adjusted EBITDA margin reflects improved performance across HEALWELL's operating segments and a 7% reduction in total operating expenses. Net loss
Technology, Healthcare and Hospitals
2026-11-09 7:13 PM EST | HEALWELL AI
WELLSTAR Achieves Record Quarterly Revenue of $24.1 Million and 33% Revenue Growth in First Quarter Reporting as a Public Company
WELLSTAR achieved quarterly revenue of $24.1 million in Q3-2026, an increase of 33% as compared to Q3-2025, with growth across all three product lines, led by Billing and Practice Management, an increase of 54%, to $9.0 million. Annual Recurring Revenue (ARR)(2) reached $83.7 million as of September 30, 2026, an increase of 27% year over year. WELLSTAR achieved Adjusted EBITDA(1) of $5.1 million in Q3-2026, an increase of 10% from Q2-2026, represent
Technology, Healthcare and Hospitals
2026-11-09 4:00 PM EST | WELLSTAR Technologies Corp.
WELL Health Reports Record Q3-2026 Revenue; Canadian Patient Services Adjusted EBITDA Up 82%, Reaching $100 Million Annualized Run-Rate Milestone One Quarter Ahead of Plan
WELL achieved quarterly revenue of $407.4 million in Q3-2026, an increase of 12% compared to Q3-2025, driven by strong growth in the Company's Canadian Patient Services business where quarterly revenue increased by 49% to $164.9 million in Q3-2026 compared to Q3-2025. Excluding the impact of Circle Medical Deferrals(2), revenue increased 17% year-over-year from $347.0 million in Q3-2025. WELL achieved Adjusted EBITDA(1) of $50.9 million in Q3-2026,
Technology, Computer Software, Healthcare and Hospitals, Health
2026-11-09 4:00 PM EST | WELL Health Technologies Corp.
Adia Med CEO Larry Powalisz Issues Open Letter on Leadership Journey, Research Mission, and Progress Since 2024
Winter Park, Florida--(Newsfile Corp. - November 9, 2026) - Adia Med Inc. (OTCQB: ADIA) today released the following open letter from Chief Executive Officer Larry Powalisz outlining the company's progress since the January 2024 leadership transition, its regenerative medicine research mission, and efforts to generate evidence that could support broader access to investigational therapies. An Open Letter from Larry Powalisz, CEO of Adia Med Inc. November 5, 2026 Winter
Healthcare and Hospitals, Health
2026-11-09 8:00 AM EST | Adia Med Inc.